Rabeprazole 20 mg

DRUG4 trials

Sponsors

Eisai Inc., Eisai Co., Ltd., Pfizer, Lomond Therapeutics Holdings, Inc.

Conditions

Gastroesophageal Reflux DiseaseHealthyHealthy Participants

Phase 1

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

CompletedNCT04565574

Eisai Co., Ltd.Healthy Participants

Start: 2020-10-16End: 2021-03-31Updated: 2021-11-01

A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.

CompletedNCT06105983

Start: 2023-11-03End: 2024-07-19Updated: 2025-04-24

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

CompletedNCT06787131

Lomond Therapeutics Holdings, Inc.Healthy

Start: 2024-05-21End: 2025-07-04Updated: 2025-12-05

Phase 2

Maintenance Intermittent Therapy for Symptomatic GERD Patients

CompletedNCT00165841

Eisai Inc.Gastroesophageal Reflux Disease

Start: 2004-10-31End: 2008-06-30Updated: 2013-05-20

Related Papers

Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.

2010-02-028 citations